Major changes compared to the previous edition are the broadening of KMT2A and MECOM rearrangements (-r), inclusion of NUP98 and other DGAs and abandoning the previous category of AML with RUNX1 mutation. This evidence concerns the gene RUNX1 and acute myeloid leukemia.